Infectious Disease Advisor news story
Frequent antiretroviral therapy regimen switching among virologically suppressed patients with HIV reflects a clinical shift toward treatment optimization and the streamlining of oral or long-acting injectable therapies.
Researchers conducted an observational cohort study using electronic health record data captured from 97 clinics across 21 US states and Puerto Rico. They sought to characterize trends in ART regimen switching among virologically suppressed patients with HIV infection between July 2024 and June 2025.
Read the full news story here.
/Infectious Disease Advisor requires free registration if more than 5 articles are viewed per month/
Source : Infectious Disease Advisor
Related HIV and Co-Infections News
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
[CROI 2026] HIV i-Base: Investigational HIV combinations – daily, weekly, 4- and 6-monthly…
-
[Press release] FDA approves Merck’s once-daily IDVYNSO™ (doravirine/islatravir)
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.